The Emmes Company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, The Emmes Company sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

The Emmes Company: 11 sponsored US clinical trials, none currently recruiting.

The Emmes Company sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Intra-abdominal Infection, with 1 trials.

Top-decile sponsor footprint

The Emmes Company ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED

Mitochondrial Video Assessment Source Material Study

NCT06180421
COMPLETED

Duchenne Muscular Dystrophy Video Assessment Registry

NCT05712447
TERMINATED

Limb-Girdle Video Assessment

NCT05528757
COMPLETED

Angelman Syndrome Video Assessment (ASVA) Source Material Study

NCT05637697
COMPLETED Phase 1

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
COMPLETED Phase 3

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
COMPLETED Phase 1

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

NCT00621192
TERMINATED Phase 2

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

NCT00393380
COMPLETED Phase 2

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

NCT00135668
COMPLETED Phase 3

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
COMPLETED Phase 2

Lorazepam Sedation for Critically Ill Children

NCT00109395

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Intra-abdominal Infection 1
Central Retinal Vein Occlusion 1
Necrotizing Enterocolitis 1
Duchenne Muscular Dystrophy 1

How the The Emmes Company early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 9 completed (82%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Intra-abdominal Infection (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

The Emmes Company: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

The Emmes Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share The Emmes CompanyAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
The Emmes Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

The Emmes Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this The Emmes Company page

11 registered trials is a research-attention snapshot, not an endorsement of The Emmes Company or any single study.

  • None of The Emmes Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Intra-abdominal Infection is the condition The Emmes Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Intra-abdominal Infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. The Emmes Company pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.